Skip to main content
. 2018 Jul 30;8(16):4295–4304. doi: 10.7150/thno.26370

Figure 3.

Figure 3

Tracer uptake (%ID/kg) per healthy tissue and in blood for 89Zr-lumretuzumab, 89Zr-MMOT0530A, 89Zr-bevacizumab and 89Zr-trastuzumab (left to right) 4 days post tracer injection. Each dot represents an individual patient; mean is plotted per tracer.